WillowV1, Main, Exploration, bibRecord, 001317

Dopamine D1 and D2 receptor antagonism effects on rat ultrasonic vocalizations.

Identifieur interne : 001317 ( Main/Exploration ); précédent : 001316; suivant : 001318

Dopamine D1 and D2 receptor antagonism effects on rat ultrasonic vocalizations.

Auteurs : Lauren E. Ringel [États-Unis] ; Jaime N. Basken ; Laura M. Grant ; Michelle R. Ciucci

Source :

Behavioural brain research [ 1872-7549 ] ; 2013.

RBID : pubmed:23764460

Descripteurs français

KwdFr :
- Analyse de variance (MeSH), Animaux (MeSH), Antagonistes de la dopamine (pharmacologie), Cortex préfrontal (effets des médicaments et des substances chimiques), Cortex préfrontal (métabolisme), Femelle (MeSH), Interactions médicamenteuses (MeSH), Mâle (MeSH), Psychoacoustique (MeSH), Rat Long-Evans (MeSH), Rats (MeSH), Réaction de catalepsie (effets des médicaments et des substances chimiques), Récepteur D2 de la dopamine (métabolisme), Récepteur dopamine D1 (métabolisme), Science des ultrasons (MeSH), Stimulation acoustique (MeSH), Temps de réaction (effets des médicaments et des substances chimiques), Vocalisation animale (effets des médicaments et des substances chimiques).
MESH :
- effets des médicaments et des substances chimiques : Cortex préfrontal, Réaction de catalepsie, Temps de réaction, Vocalisation animale.
- métabolisme : Cortex préfrontal, Récepteur D2 de la dopamine, Récepteur dopamine D1.
- pharmacologie : Antagonistes de la dopamine.
- Analyse de variance, Animaux, Femelle, Interactions médicamenteuses, Mâle, Psychoacoustique, Rat Long-Evans, Rats, Science des ultrasons, Stimulation acoustique.

English descriptors

KwdEn :
- Acoustic Stimulation (MeSH), Analysis of Variance (MeSH), Animals (MeSH), Dopamine Antagonists (pharmacology), Drug Interactions (MeSH), Female (MeSH), Freezing Reaction, Cataleptic (drug effects), Male (MeSH), Prefrontal Cortex (drug effects), Prefrontal Cortex (metabolism), Psychoacoustics (MeSH), Rats (MeSH), Rats, Long-Evans (MeSH), Reaction Time (drug effects), Receptors, Dopamine D1 (metabolism), Receptors, Dopamine D2 (metabolism), Ultrasonics (MeSH), Vocalization, Animal (drug effects).
MESH :
- chemical , metabolism : Receptors, Dopamine D1, Receptors, Dopamine D2.
- chemical , pharmacology : Dopamine Antagonists.
- drug effects : Freezing Reaction, Cataleptic, Prefrontal Cortex, Reaction Time, Vocalization, Animal.
- metabolism : Prefrontal Cortex.
- Acoustic Stimulation, Analysis of Variance, Animals, Drug Interactions, Female, Male, Psychoacoustics, Rats, Rats, Long-Evans, Ultrasonics.

Abstract

Voice disorders manifest in the early stages of Parkinson disease (PD), suggesting the vulnerability of the laryngeal sensorimotor system to mild alterations in dopamine signaling. Previous research has demonstrated that manipulations of central dopamine result in acoustic changes in rat ultrasonic vocalization (USV) and selective manipulation of receptor subtypes results in dose dependent changes in call rate and complexity. However, no study has specifically focused on the influence of dopamine receptor subtypes on acoustic features of USV production. This study examined the influence of D1 and D2 receptor subtypes on voluntary laryngeal sensorimotor control (USV) and gross whole-body involvement. Rat USV acoustics and catalepsy descent time were analyzed following the administration of selective D1 and D2 receptor antagonists in isolation and in combination, and a vehicle control. Results support the hypothesis that degradations of the acoustic signal would be most severe following combined receptor antagonism (D1+D2) compared with D1 or D2 receptor antagonism alone, and the vehicle (saline) condition. In addition, results indicate that selective D1 receptor antagonism alters acoustic parameters to a greater extent than D2 receptor antagonism. Thus, dopamine receptor subtypes appear to influence acoustic parameters to different degrees. Catalepsy descent time was longest following combined dopamine receptor antagonism but was also significantly increased with selective D1 or D2 antagonism. Together, these results support the potentially different contributions receptor subtypes play in cranial and limb sensorimotor control.

DOI: 10.1016/j.bbr.2013.06.006
PubMed: 23764460
PubMed Central: PMC3742589

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001258
to stream Main, to step Curation: 001258

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine D1 and D2 receptor antagonism effects on rat ultrasonic vocalizations.</title>
<author><name sortKey="Ringel, Lauren E" sort="Ringel, Lauren E" uniqKey="Ringel L" first="Lauren E" last="Ringel">Lauren E. Ringel</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Communication Sciences and Disorders, University of Wisconsin-Madison, 1975 Willow Drive, Madison, WI 53706, USA. Lringel87@gmail.com</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Communication Sciences and Disorders, University of Wisconsin-Madison, 1975 Willow Drive, Madison, WI 53706</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Basken, Jaime N" sort="Basken, Jaime N" uniqKey="Basken J" first="Jaime N" last="Basken">Jaime N. Basken</name>
</author>
<author><name sortKey="Grant, Laura M" sort="Grant, Laura M" uniqKey="Grant L" first="Laura M" last="Grant">Laura M. Grant</name>
</author>
<author><name sortKey="Ciucci, Michelle R" sort="Ciucci, Michelle R" uniqKey="Ciucci M" first="Michelle R" last="Ciucci">Michelle R. Ciucci</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23764460</idno>
<idno type="pmid">23764460</idno>
<idno type="doi">10.1016/j.bbr.2013.06.006</idno>
<idno type="pmc">PMC3742589</idno>
<idno type="wicri:Area/Main/Corpus">001258</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001258</idno>
<idno type="wicri:Area/Main/Curation">001258</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001258</idno>
<idno type="wicri:Area/Main/Exploration">001258</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Dopamine D1 and D2 receptor antagonism effects on rat ultrasonic vocalizations.</title>
<author><name sortKey="Ringel, Lauren E" sort="Ringel, Lauren E" uniqKey="Ringel L" first="Lauren E" last="Ringel">Lauren E. Ringel</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Communication Sciences and Disorders, University of Wisconsin-Madison, 1975 Willow Drive, Madison, WI 53706, USA. Lringel87@gmail.com</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Communication Sciences and Disorders, University of Wisconsin-Madison, 1975 Willow Drive, Madison, WI 53706</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Basken, Jaime N" sort="Basken, Jaime N" uniqKey="Basken J" first="Jaime N" last="Basken">Jaime N. Basken</name>
</author>
<author><name sortKey="Grant, Laura M" sort="Grant, Laura M" uniqKey="Grant L" first="Laura M" last="Grant">Laura M. Grant</name>
</author>
<author><name sortKey="Ciucci, Michelle R" sort="Ciucci, Michelle R" uniqKey="Ciucci M" first="Michelle R" last="Ciucci">Michelle R. Ciucci</name>
</author>
</analytic>
<series><title level="j">Behavioural brain research</title>
<idno type="eISSN">1872-7549</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acoustic Stimulation (MeSH)</term>
<term>Analysis of Variance (MeSH)</term>
<term>Animals (MeSH)</term>
<term>Dopamine Antagonists (pharmacology)</term>
<term>Drug Interactions (MeSH)</term>
<term>Female (MeSH)</term>
<term>Freezing Reaction, Cataleptic (drug effects)</term>
<term>Male (MeSH)</term>
<term>Prefrontal Cortex (drug effects)</term>
<term>Prefrontal Cortex (metabolism)</term>
<term>Psychoacoustics (MeSH)</term>
<term>Rats (MeSH)</term>
<term>Rats, Long-Evans (MeSH)</term>
<term>Reaction Time (drug effects)</term>
<term>Receptors, Dopamine D1 (metabolism)</term>
<term>Receptors, Dopamine D2 (metabolism)</term>
<term>Ultrasonics (MeSH)</term>
<term>Vocalization, Animal (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de variance (MeSH)</term>
<term>Animaux (MeSH)</term>
<term>Antagonistes de la dopamine (pharmacologie)</term>
<term>Cortex préfrontal (effets des médicaments et des substances chimiques)</term>
<term>Cortex préfrontal (métabolisme)</term>
<term>Femelle (MeSH)</term>
<term>Interactions médicamenteuses (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Psychoacoustique (MeSH)</term>
<term>Rat Long-Evans (MeSH)</term>
<term>Rats (MeSH)</term>
<term>Réaction de catalepsie (effets des médicaments et des substances chimiques)</term>
<term>Récepteur D2 de la dopamine (métabolisme)</term>
<term>Récepteur dopamine D1 (métabolisme)</term>
<term>Science des ultrasons (MeSH)</term>
<term>Stimulation acoustique (MeSH)</term>
<term>Temps de réaction (effets des médicaments et des substances chimiques)</term>
<term>Vocalisation animale (effets des médicaments et des substances chimiques)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Dopamine D1</term>
<term>Receptors, Dopamine D2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Dopamine Antagonists</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Freezing Reaction, Cataleptic</term>
<term>Prefrontal Cortex</term>
<term>Reaction Time</term>
<term>Vocalization, Animal</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Cortex préfrontal</term>
<term>Réaction de catalepsie</term>
<term>Temps de réaction</term>
<term>Vocalisation animale</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Prefrontal Cortex</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cortex préfrontal</term>
<term>Récepteur D2 de la dopamine</term>
<term>Récepteur dopamine D1</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antagonistes de la dopamine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Acoustic Stimulation</term>
<term>Analysis of Variance</term>
<term>Animals</term>
<term>Drug Interactions</term>
<term>Female</term>
<term>Male</term>
<term>Psychoacoustics</term>
<term>Rats</term>
<term>Rats, Long-Evans</term>
<term>Ultrasonics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse de variance</term>
<term>Animaux</term>
<term>Femelle</term>
<term>Interactions médicamenteuses</term>
<term>Mâle</term>
<term>Psychoacoustique</term>
<term>Rat Long-Evans</term>
<term>Rats</term>
<term>Science des ultrasons</term>
<term>Stimulation acoustique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Voice disorders manifest in the early stages of Parkinson disease (PD), suggesting the vulnerability of the laryngeal sensorimotor system to mild alterations in dopamine signaling. Previous research has demonstrated that manipulations of central dopamine result in acoustic changes in rat ultrasonic vocalization (USV) and selective manipulation of receptor subtypes results in dose dependent changes in call rate and complexity. However, no study has specifically focused on the influence of dopamine receptor subtypes on acoustic features of USV production. This study examined the influence of D1 and D2 receptor subtypes on voluntary laryngeal sensorimotor control (USV) and gross whole-body involvement. Rat USV acoustics and catalepsy descent time were analyzed following the administration of selective D1 and D2 receptor antagonists in isolation and in combination, and a vehicle control. Results support the hypothesis that degradations of the acoustic signal would be most severe following combined receptor antagonism (D1+D2) compared with D1 or D2 receptor antagonism alone, and the vehicle (saline) condition. In addition, results indicate that selective D1 receptor antagonism alters acoustic parameters to a greater extent than D2 receptor antagonism. Thus, dopamine receptor subtypes appear to influence acoustic parameters to different degrees. Catalepsy descent time was longest following combined dopamine receptor antagonism but was also significantly increased with selective D1 or D2 antagonism. Together, these results support the potentially different contributions receptor subtypes play in cranial and limb sensorimotor control. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23764460</PMID>
<DateCompleted><Year>2013</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7549</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>252</Volume>
<PubDate><Year>2013</Year>
<Month>Sep</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Behavioural brain research</Title>
<ISOAbbreviation>Behav Brain Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Dopamine D1 and D2 receptor antagonism effects on rat ultrasonic vocalizations.</ArticleTitle>
<Pagination><MedlinePgn>252-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbr.2013.06.006</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0166-4328(13)00350-1</ELocationID>
<Abstract><AbstractText>Voice disorders manifest in the early stages of Parkinson disease (PD), suggesting the vulnerability of the laryngeal sensorimotor system to mild alterations in dopamine signaling. Previous research has demonstrated that manipulations of central dopamine result in acoustic changes in rat ultrasonic vocalization (USV) and selective manipulation of receptor subtypes results in dose dependent changes in call rate and complexity. However, no study has specifically focused on the influence of dopamine receptor subtypes on acoustic features of USV production. This study examined the influence of D1 and D2 receptor subtypes on voluntary laryngeal sensorimotor control (USV) and gross whole-body involvement. Rat USV acoustics and catalepsy descent time were analyzed following the administration of selective D1 and D2 receptor antagonists in isolation and in combination, and a vehicle control. Results support the hypothesis that degradations of the acoustic signal would be most severe following combined receptor antagonism (D1+D2) compared with D1 or D2 receptor antagonism alone, and the vehicle (saline) condition. In addition, results indicate that selective D1 receptor antagonism alters acoustic parameters to a greater extent than D2 receptor antagonism. Thus, dopamine receptor subtypes appear to influence acoustic parameters to different degrees. Catalepsy descent time was longest following combined dopamine receptor antagonism but was also significantly increased with selective D1 or D2 antagonism. Together, these results support the potentially different contributions receptor subtypes play in cranial and limb sensorimotor control. </AbstractText>
<CopyrightInformation>Copyright © 2013 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ringel</LastName>
<ForeName>Lauren E</ForeName>
<Initials>LE</Initials>
<AffiliationInfo><Affiliation>Department of Communication Sciences and Disorders, University of Wisconsin-Madison, 1975 Willow Drive, Madison, WI 53706, USA. Lringel87@gmail.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Basken</LastName>
<ForeName>Jaime N</ForeName>
<Initials>JN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Grant</LastName>
<ForeName>Laura M</ForeName>
<Initials>LM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ciucci</LastName>
<ForeName>Michelle R</ForeName>
<Initials>MR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 DC005935</GrantID>
<Acronym>DC</Acronym>
<Agency>NIDCD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 DC009401</GrantID>
<Acronym>DC</Acronym>
<Agency>NIDCD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>1P30 DC 010754</GrantID>
<Acronym>DC</Acronym>
<Agency>NIDCD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 DC010754</GrantID>
<Acronym>DC</Acronym>
<Agency>NIDCD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 DC008149</GrantID>
<Acronym>DC</Acronym>
<Agency>NIDCD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>06</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Behav Brain Res</MedlineTA>
<NlmUniqueID>8004872</NlmUniqueID>
<ISSNLinking>0166-4328</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000161" MajorTopicYN="N">Acoustic Stimulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018492" MajorTopicYN="N">Dopamine Antagonists</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D046352" MajorTopicYN="N">Freezing Reaction, Cataleptic</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011571" MajorTopicYN="N">Psychoacoustics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020318" MajorTopicYN="N">Rats, Long-Evans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014465" MajorTopicYN="Y">Ultrasonics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014828" MajorTopicYN="N">Vocalization, Animal</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antagonism</Keyword>
<Keyword MajorTopicYN="N">Dopamine</Keyword>
<Keyword MajorTopicYN="N">Rat</Keyword>
<Keyword MajorTopicYN="N">Receptor</Keyword>
<Keyword MajorTopicYN="N">Sensorimotor control</Keyword>
<Keyword MajorTopicYN="N">Ultrasonic vocalization</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year>
<Month>04</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2013</Year>
<Month>05</Month>
<Day>31</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>06</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>10</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23764460</ArticleId>
<ArticleId IdType="pii">S0166-4328(13)00350-1</ArticleId>
<ArticleId IdType="doi">10.1016/j.bbr.2013.06.006</ArticleId>
<ArticleId IdType="pmc">PMC3742589</ArticleId>
<ArticleId IdType="mid">NIHMS491426</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Neurology. 2000 Jan 25;54(2):458-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10668714</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Exp Brain Res. 2010 Mar;201(3):401-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20012947</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Behav Brain Res. 2007 Sep 4;182(2):274-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17449117</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharmacol. 1985 Nov 5;117(2):179-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2866970</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Behav Brain Res. 2013 Jan 15;237:157-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23018122</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Behav Neurosci. 2000 Oct;114(5):983-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11085613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Biochem Behav. 2010 Sep;96(3):251-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20493210</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Psychopharmacology (Berl). 2013 Feb;225(4):853-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23052567</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mov Disord. 2003 Mar;18(3):231-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12621626</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neurophysiol. 2009 Aug;102(2):1193-205</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19535485</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Physiol Behav. 2008 Mar 18;93(4-5):766-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18191963</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neurophysiol. 2011 Nov;106(5):2580-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21832032</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Behav Neurosci. 1988 Oct;102(5):748-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2904271</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Brain Res. 2010 Jun 23;1341:3-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20233583</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mov Disord. 2009 Jul 15;24(9):1352-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19425089</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Neurosci. 1996 Oct;19(10):417-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8888518</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Exp Brain Res. 2009 Apr;194(4):587-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19247644</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Rev. 2011 Mar;63(1):182-217</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21303898</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Brain Cogn. 2004 Oct;56(1):24-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15380872</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neural Transm (Vienna). 2011 May;118(5):821-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20862500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Behav Neurosci. 2009 Apr;123(2):328-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19331456</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Psychopharmacology (Berl). 2010 Jul;211(1):1-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20443111</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Behav Neurosci. 2001 Aug;115(4):940-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11508733</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Acoust Soc Am. 2010 Aug;128(2):EL75-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20707418</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Neurobiol. 2013 Jun;23(3):310-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23375168</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Behav Brain Res. 2007 Sep 4;182(2):261-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17467067</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mov Disord. 1995 Sep;10(5):562-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8552106</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Voice. 2008 May;22(3):365-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17368837</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurosci Biobehav Rev. 2011 Oct;35(9):1831-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21144859</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Psychol Bull. 2002 Nov;128(6):961-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12405139</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Behav Brain Res. 2007 Sep 4;182(2):284-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17397940</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Behav Neurol. 1998;11(3):131-137</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11568413</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mov Disord. 2002;17 Suppl 3:S28-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11948753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Neurol. 2004 Sep;3(9):547-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15324723</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Commun Disord. 2010 Jul-Aug;43(4):319-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20434728</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Comp Psychol. 2008 Nov;122(4):357-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19014259</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Behav Brain Res. 2009 Jan 30;197(1):205-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18809437</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Neurosci. 2002 Jul;3(7):574-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12094213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Acoust Soc Am. 1989 Jun;85(6):2608-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2745883</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Clin North Am. 1968 Jul;52(4):835-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5742068</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurobiol Aging. 2003 Mar-Apr;24(2):197-211</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Comp Psychol. 2002 Mar;116(1):73-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11926686</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Wisconsin</li>
</region>
</list>
<tree><noCountry><name sortKey="Basken, Jaime N" sort="Basken, Jaime N" uniqKey="Basken J" first="Jaime N" last="Basken">Jaime N. Basken</name>
<name sortKey="Ciucci, Michelle R" sort="Ciucci, Michelle R" uniqKey="Ciucci M" first="Michelle R" last="Ciucci">Michelle R. Ciucci</name>
<name sortKey="Grant, Laura M" sort="Grant, Laura M" uniqKey="Grant L" first="Laura M" last="Grant">Laura M. Grant</name>
</noCountry>
<country name="États-Unis"><region name="Wisconsin"><name sortKey="Ringel, Lauren E" sort="Ringel, Lauren E" uniqKey="Ringel L" first="Lauren E" last="Ringel">Lauren E. Ringel</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/WillowV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001317 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001317 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    WillowV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23764460
   |texte=   Dopamine D1 and D2 receptor antagonism effects on rat ultrasonic vocalizations.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23764460" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a WillowV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Nov 17 16:35:40 2020. Site generation: Tue Nov 17 16:39:32 2020

	Serveur d'exploration sur le saule
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le saule

Dopamine D1 and D2 receptor antagonism effects on rat ultrasonic vocalizations.

Dopamine D1 and D2 receptor antagonism effects on rat ultrasonic vocalizations.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki